China Biologic Products Holdings Inc (NASDAQ:CBPO) – Equities research analysts at Jefferies Financial Group issued their Q1 2019 earnings per share estimates for China Biologic Products in a research report issued to clients and investors on Monday, March 11th. Jefferies Financial Group analyst J. Wong expects that the biopharmaceutical company will post earnings of $0.96 per share for the quarter. Jefferies Financial Group currently has a “Underperform” rating and a $62.00 price target on the stock. Jefferies Financial Group also issued estimates for China Biologic Products’ Q2 2019 earnings at $0.93 EPS, Q3 2019 earnings at $0.92 EPS, Q4 2019 earnings at $0.93 EPS, FY2019 earnings at $3.73 EPS, FY2020 earnings at $3.96 EPS and FY2021 earnings at $4.24 EPS.
Several other research analysts have also recently commented on the stock. BidaskClub upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Wednesday, December 5th. Credit Suisse Group set a $88.00 target price on shares of China Biologic Products and gave the stock a “hold” rating in a report on Friday, March 8th. ValuEngine upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Zacks Investment Research upgraded shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Monday, January 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $78.00.
Shares of CBPO opened at $84.98 on Thursday. China Biologic Products has a one year low of $60.08 and a one year high of $107.44. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 5.62 and a beta of 1.25.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, March 6th. The biopharmaceutical company reported $0.76 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.83 by ($0.07). China Biologic Products had a return on equity of 9.54% and a net margin of 27.43%. The business had revenue of $114.90 million during the quarter, compared to analyst estimates of $116.35 million. During the same period in the prior year, the firm earned $1.32 EPS. The business’s revenue for the quarter was up 27.5% on a year-over-year basis.
Institutional investors and hedge funds have recently made changes to their positions in the business. AdvisorNet Financial Inc acquired a new position in shares of China Biologic Products in the fourth quarter worth about $57,000. Cutler Group LP boosted its holdings in shares of China Biologic Products by 58.4% in the fourth quarter. Cutler Group LP now owns 1,356 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 500 shares during the period. Amundi Pioneer Asset Management Inc. boosted its holdings in shares of China Biologic Products by 79.9% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,100 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 933 shares during the period. Legal & General Group Plc boosted its holdings in shares of China Biologic Products by 25.2% during the third quarter. Legal & General Group Plc now owns 2,357 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 475 shares during the period. Finally, Gabelli Funds LLC acquired a new stake in shares of China Biologic Products during the third quarter worth approximately $232,000. Institutional investors own 43.34% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Featured Article: Google Finance Portfolio
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.